Thomas Dyrberg

Thomas Dyrberg is a Senior Partner in Novo Ventures, Novo A/S.

Thomas Dyrberg joined Novo A/S in 2000. He is a member of the boards of directors of AlloCure Inc., Delenex Therapeutics AG, Imagen Biotech Inc., Lux Biosciences Inc., Ophthotech Corporation and Veloxis Pharmaceuticals A/S, and was a board member of BioMimetic Therapeutics, Inc., Gloucester Pharmaceuticals, HemoFocus ApS and Sapphire Therapeutics, Inc.

Thomas held research positions at the Hagedorn Research Institute, Denmark, and at the Scripps Research Institute, La Jolla, USA. In 1990, he joined Novo Nordisk A/S, initially working in Health Care Discovery on various aspects of diabetes immunology and pathogenesis, and from 1996 in Health Care Clinical Drug Development as an International Clinical Project Manager.

Thomas obtained an MD degree from the University of Copenhagen in 1981 and a DMSc degree, also from the University of Copenhagen in 1986.